Myriad Genetics - MYGN Stock Forecast, Price & News

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Myriad Genetics Stock Performance

NASDAQ:MYGN traded down $0.46 on Friday, reaching $24.78. The stock had a trading volume of 2,915 shares, compared to its average volume of 552,851. Myriad Genetics has a 1 year low of $16.02 and a 1 year high of $36.95. The business has a 50 day moving average price of $22.02 and a 200 day moving average price of $22.94.

Myriad Genetics (NASDAQ:MYGN - Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. Myriad Genetics had a negative return on equity of 3.44% and a negative net margin of 2.62%. The business had revenue of $179.30 million during the quarter, compared to analysts' expectations of $170.05 million. During the same quarter in the previous year, the business posted $0.03 EPS. The firm's quarterly revenue was down 5.3% compared to the same quarter last year. Analysts anticipate that Myriad Genetics will post -0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MYGN. StockNews.com cut Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, July 13th. Cowen boosted their price objective on Myriad Genetics to $32.00 in a report on Tuesday, August 9th. TheStreet cut shares of Myriad Genetics from a "c-" rating to a "d+" rating in a research report on Friday, June 3rd. Finally, SVB Leerink lifted their price target on Myriad Genetics from $26.00 to $30.00 and gave the company a "market perform" rating in a report on Friday, August 5th.

Insider Activity

In other Myriad Genetics news, Director Daniel K. Spiegelman sold 6,424 shares of the stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $19.25, for a total transaction of $123,662.00. Following the transaction, the director now owns 33,980 shares in the company, valued at $654,115. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.80% of the stock is currently owned by insiders.